

K110436  
APR 20 2011

## 5 510(k) Summary

**Introduction:** According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

**Submitter:** Fujirebio Diagnostics, Inc.  
940 Crossroads Blvd  
Seguin, TX 78155  
(830) 372-1391 ex. 210  
Establishment Registration Number: 1643621

**Contact Person:** Kent Pruett

**Device Name:** FDI Glucose Control for Aviva

**Common Name:** Single Analyte Control Solution, All Types (Assayed and Unassayed)

**Classification Name:** Quality Control Material (assayed and unassayed).

**Classification:** Class I per 21 CFR 862.1660

**Product Code:** 75 JJX

**Panel:** Chemistry

**Predicate Devices:** Name: ACCU-CHEK Aviva Control Level 1  
Manufacturer: Roche Diagnostics  
510(k) No.: k043474

**Device Description:** The FDI Glucose Control for Aviva consists of a viscosity-adjusted, aqueous liquid control solution containing a known quantity of glucose. The product is packaged in plastic dropper tipped bottles for easy application of the control solutions to the test strips and a red coloration to aid the user to visually confirm application of the control. The product is non-hazardous and contains no human or animal derived materials.

**Intended Use:** The FDI Glucose Control for Aviva is intended for in vitro diagnostic use (i.e. for external use only) by healthcare professionals and in the home by people

with diabetes mellitus to assess the performance of  
ACCU-CHEK Aviva Blood Glucose Monitor.

**Comparison to Predicate  
Devices:**

Characteristic/ Aspect	Predicate Device No. 1	New Product
Name	ACCU-CHEK Aviva Control Level 1	FDI Glucose Control for Aviva
510(k), Date	K043474 04/27/2005	
Number of Levels	1	1
Analyte	Glucose	Glucose
Target Range (mg/dL)	25 – 55 <sup>(1)</sup>	19 – 51 <sup>(2)</sup>
Container	Plastic bottle with dropper-tip	Plastic bottle with dropper-tip
Fill Volume	2.5 mL	3.6 mL
Color	Red	Red
Matrix	Glucose, buffer, salts, non- reactive ingredients, preservative, FD & C Blue #1	Buffered aqueous solution of D- Glucose, a viscosity modifier, preservatives, and other non- reactive ingredients
Indications for Use	Checks that the meter and test strips are working properly to give reliable results.	To check the performance of the ACCU-CHEK Aviva Blood Glucose System.
Target Population	Professional and home use	Professional and home use

<sup>(1)</sup> Derived from the control ranges assigned by the manufacturer.

<sup>(2)</sup> Based on a +/- 5% glucose concentration variability lot-to-lot and +/- 15 mg/dl range

**Performance Studies:** Tests were performed to verify specific performance characteristics:

1. Real Time Stability
2. Open Vial Stability
3. Test precision

**Conclusion:** Comparison of the performance characteristics, formulation and intended use support the claim of substantial equivalence.



Fujirebio Diagnostics, Inc.  
c/o Kent Pruett  
Director of Quality and Regulatory Affairs  
940 Crossroads Blvd.  
Seguin, TX 78155

Food and Drug Administration  
10903 New Hampshire Avenue  
Silver Spring, MD 20993

**APR 20 2011**

Re: k110436  
Trade Name: FDI Glucose Control Solution for Aviva  
Regulation Number: 21 CFR 862.1660  
Regulation Name: single (specified) analyte controls (assayed and unassayed)  
Regulatory Class: Class I, reserved  
Product Codes: JJX  
Dated: February 8, 2011  
Received: February 15, 2011

Dear Mr. Pruett:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of *In Vitro* Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read 'CH', followed by a long horizontal line extending to the right.

Courtney Harper, Ph.D.  
Director  
Division of Chemistry and Toxicology  
Office of *In Vitro* Diagnostic Device  
Evaluation and Safety  
Center for Devices and Radiological Health

Enclosure

510(k) Premarket Notification: FDI Glucose Control for Aviva  
Fujirebio Diagnostics, Inc.

**4 Indications for Use Statement**

510(k) Number (if known): K110436

Device Name: FDI Glucose Control for Aviva

**Indications for Use:**

For in vitro diagnostic use (i.e. for external use only) by healthcare professionals and in the home by people with diabetes mellitus to assess the performance of the Aviva Blood Glucose Monitor.


Prescription Use X  
(21 CFR Part 801 Subpart D)

AND/OR

Over-The-Counter Use X  
(21 CFR Part 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)



Division Sign-Off  
Office of In Vitro Diagnostic Device  
Evaluation and Safety

510(k) K110436